Treatment interruption appears safe in a subgroup of
HIV patients with preserved immune function, researchers report in the
May 15th issue of the Journal of Infectious Diseases.
"In general, once highly active antiretroviral therapy [HAART] is
started, it should not be stopped," lead author Dr. Daniel J. Skiest
told Reuters Health. "There may be selected patients who can interrupt
therapy with a low risk of adverse outcomes."
"This would apply to patients who never had a low CD4 cell count or
any HIV-related complications and are currently virologically
suppressed on HAART," he added.
Dr. Skiest, of the Baystate Medical Center, Springfield,
Massachusetts, and colleagues prospectively studied treatment
interruption in 167 HIV-infected patients receiving HAART who had CD4+
cell counts below 350 cells per cubic millimeter.
After 96 weeks, of the patients who completed follow-up, 17 had CD4+
cell counts at or below 350 cells per cubic millimeter. At this point,
46 other patients had resumed ART and 5 had died from causes not
related to HIV or AIDS.
Overall, a higher nadir in CD4+ cell count, a lower HIV load before
ART, and an HIV load of 50 copies/mL at the time of treatment
interruption predicted a longer interval before any adverse findings.
Although the approach was successful in some patients, Dr. Skiest
stressed that "therapy interruption should only be undertaken with the
guidance of the patient's HIV clinician, and careful monitoring is
important."
J Infect Dis 2007;195:1426-1436.
Copyright©
2007 Reuters Limited. All rights reserved. Republication or
redistribution of Reuters content, including by framing or similar
means, is expressly prohibited without the prior written consent of
Reuters. Reuters shall not be liable for any errors or delays in the
content, or for any actions taken in reliance thereon. Reuters and the
Reuters sphere logo are registered trademarks and trademarks of the
Reuters group of companies around the world.
